CTOs on the Move

AZPerio

www.azperio.com

 
AZPerio is home to the state’s leading board-certified periodontists, expertly guided by a patient-first philosophy and collaborative approach. With eight locations throughout Arizona, we are committed to client service, clinical excellence and providi...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.azperio.com
  • 5300, North Central Avenue
    Phoenix, AZ USA 85012
  • Phone: 480.991.0090

Executives

Name Title Contact Details

Similar Companies

Caldera Pharmaceuticals

Caldera Pharmaceuticals is a Los Alamos, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Znomics

Znomics is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABIANT INC

ABIANT INC is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug. The resulting, new therapeutic creates a more targeted molecule with the goal of improving treatment outcomes and improving compliance with treatment regimens. Our initial development areas are in oncology and infectious disease.